Fig. 6. EHD1 correlates with EGFR-TKI sensitivity and patient survival in NSCLC.

a The EHD1 expression in squamous cell lung carcinoma samples, lung adenocarcinoma samples and para-carcinoma normal lung tissues obtained from The Cancer Genome Atlas (TCGA) database. b The expression of EHD1 in PC9 and HCC827 cells treated with EGFR-TKI or with DMSO from TCGA. c, d Kaplan–Meier analysis of the 5-year OS (left panel) and DFS (right panel) of patients with NSCLC for whom both OS and DFS information was available in the TCGA lung cancer data set. The patients were stratified by high (greater than the median, n = 195) vs. low (greater than or equal to the median, n = 197) expression of EHD1. e, f Further analyse OS and DFS for 325 NSCLC patients in stages I–II and 62 patients in stages III–IV in the TCGA lung cancer cohort, respectively